Cognition Therapeutics Inc (CGTX) stock saw a modest uptick, ending the day at $0.65 which represents a slight increase of $0.04 or 6.56% from the prior close of $0.61. The stock opened at $0.61 and ...

On Friday, Cognition Therapeutics Inc (CGTX) stock saw a modest uptick, ending the day at $0.63 which represents no change from the prior close of of $0.63. The stock opened at $0.64 and touched a low ...

Fintel reports that on December 19, 2024, B. Riley Securities upgraded their outlook for Cognition Therapeutics ...

B. Riley upgraded Cognition Therapeutics (CGTX) to Buy from Neutral with a $1.50 price target Pick the best stocks and maximize your ...

H.C. Wainwright raised the firm’s price target on Cognition Therapeutics (CGTX) to $6 from $5 and keeps a Buy rating on the shares. The company ...

Traders wasted no time buying up shares of Cognition Therapeutics, Inc. (Nasdaq:CGTX), with the current bid sitting at ...

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Merck & Co. Inc. has turned to Asia for a second time to get into the GLP-1 market. Shanghai-based Hansoh Pharmaceutical Group Co. Ltd. has licensed HS-10535, an investigational preclinical oral small ...

Improvements Across Measures of Behavior, Function, Cognition and Movement - - Expediting Plans to Advance CT1812 into Late-Stage Trials - - Full Results to be Presented at International Lewy Body ...

Cognition Therapeutics' CT1812 improves dementia with Lewy bodies outcomes, reducing anxiety, hallucinations, and functional ...

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining exploration companies often lose money for years before finding success with a new ...

Cognition Therapeutics (CGTX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong ...